(The Center Square) – AstraZeneca has now joined Pfizer in agreeing to sell its drugs to state Medicaid programs at “most-favored-nation” pricing and deeply discounted rates on TrumpRx.gov
But what does that mean?
Last week, President Donald Trump and Health and Human Services officials announced the forthcoming creation of TrumpRx, a direct-to-consumer website where Americans will be able to buy some of their medications for less. They also unveiled the first-of-its-kind deal they’d reached with pharmaceutical giant Pfizer on drug pricing for Medicaid – a deal they’ve now secured with AstraZeneca, as well.
The drug manufacturers have also mentioned selling all of their new drugs at most-favored-nation pricing, though the implications of this are still unclear.
How it started
In May, Trump signed the executive order “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” aimed at addressing inequities in what the U.S. pays for medical drugs compared to other wealthy countries.
Sometimes Americans pay 10 times more than citizens of an economic peer country for the same medication. Most of the time, it’s more like two or three times as much. Trump has framed it as other countries capitalizing on innovation underwritten by Americans, as the U.S. funds a large portion of pharmaceutical research and development.
“Americans should not be forced to subsidize low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States,” the order reads.
What is “most-favored-nation pricing”?
Most-favored-nation pricing means the U.S. would pay no more for a drug than the lowest price paid by peer nations.
Where Big Pharma comes in
Trump threatened pharmaceutical companies that didn’t make the shift with “aggressive action” from his administration. Pfizer is the first to have reached an agreement with the administration and complied with the MFN directive, and now, AstraZeneca.
Who benefits?
Pfizer and AstraZeneca have agreed to sell their drugs to state Medicaid programs at most-favored-nation pricing. It’s not yet clear how the new pricing compares to what Medicaid has been paying, but it could result in real savings for states.
AstraZeneca CEO Pascal Soriot said Friday he believes the American economy will also benefit from the “equalization” of drug costs across countries.
“It’s a big win for patients and the healthcare system as a whole, but it’s also a big win for the economy and for taxpayers, because it supports rebalancing the cost of innovation across wealthy nations. For too long, America has shouldered a disproportionate portion of the world’s R&D,” Soriot said. “That imbalance is not sustainable.”
These companies have also committed to selling all new drugs at most-favored-nation pricing, though it’s unclear if this would again only apply to Medicaid programs and when it is supposed to go into effect.
“We also have MFN for all new prescription drugs, Mr. President. By the time this term is done, 95% of all drugs sold in America, branded drugs and generic will be available at most favored nation drug pricing,” Soriot said.
TrumpRx: Discounted prescription drugs sans middleman…
Some pharmaceutical manufacturers have recently begun offering some of their products on their websites for much less. TrumpRx is jumping on this direct-to-consumer bandwagon and will function as a kind of online marketplace for people looking to buy deeply discounted drugs.
So what’s the catch?
But people using TrumpRx can’t use insurance. There is no middleman with direct-to-consumer products – no CVS Pharmacy and no insurer, either. So TrumpRx is really for people without insurance or who have lost it temporarily or for instances where it makes more sense to pay a discounted price than to use insurance, like when insurance doesn’t cover a particular drug.
Pfizer has shared some of the drugs it has agreed to offer through the TrumpRx platform, some of which will be available at an 80% to 85% discount. Others will be discounted less, like Xeljanz. Xeljanz is an oral medication for ulcerative colitis and some types of arthritis, and patients can purchase it at 60% of its sticker price – which unfortunately is still over $3,600 per month.
In most cases, a medication will likely be cheaper (or much, much cheaper) with insurance. In Xeljanz’s case, it’s often covered through insurance and in some cases, patients pay only $25 a month, as the New York Times reported.
However, Trump said Friday drug prices would be going down “100%, 400%, 600% – 1,000% in some cases” and that these deals would “have a huge impact” on Medicare and Medicaid, but also on Social Security.
He gave an example of an expected 654% price reduction.
“One particular drug that’s hot, very hot – 654% on inhalers, COPD and asthma, as well as certain diabetics medications – they’re going to be averaging about 654% reduction in price,” he said.
Other downsides
Most of the cost of a drug comes from research and development, and the president has said the U.S. pays a “disproportionate amount” of those costs. Director of Medicare Chris Klomp has said the U.S. “[drives] more than 50% of global R and D, 50% of revenues, nearly 70% of profits” for pharmaceutical companies.
Some have said America’s new pricing arrangement will harm pharmaceutical R & D.
“The Trump administration is right to focus on foreign countries free riding off American innovation, but the administration needs to do more to address unfair practices abroad,” said the Pharmaceutical Research and Manufacturers of America, or PHRMA, in a statement shared with The Center Square.
“Other countries routinely undervalue medicines and limit their citizens’ access to the newest treatments. Most Favored Nation policies that would import these same prices into the U.S. would result in less access to treatments and cures and reduced investment in manufacturing and R&D.”
Does all of this actually make a difference?
The vast majority of Americans (92%, in fact, according to Census Bureau data) have health insurance and likely won’t need to use TrumpRx in most situations, from what is currently known about the platform.
And despite Pfizer’s agreement to sell its drugs to Medicaid programs at most-favored-nation pricing, Medicaid enrollees likely won’t notice much of a difference either, since they already get their prescriptions at little to no cost.
And it’s unclear at this time what the intended scope is for Pfizer and AstraZeneca’s new drugs to be offered at MFN pricing.
But if seen as a part of a broader movement in government for greater transparency in health care, the news isn’t insignificant.
A larger push for transparency
There’s been a concerted government effort in recent years to push for more transparency in an incredibly complex industry with inscrutable pricing. In his first term, Trump issued some executive orders that required hospitals and insurance companies to publicly disclose some pricing information. The Biden administration doubled down on this initiative by ramping up enforcement measures and noncompliance penalties and creating new requirements for prescription drug reporting and price comparison tools.
Chris O’Dell, a spokesperson for health care price transparency platform Turquoise Health, said the deal for MFN pricing and the development of TrumpRx will continue to advance price transparency in health care.
“I think what they’re doing is making a big splash and casting eyes and a conceptual need for transparency onto one of the most opaque and unaffordable corners of health care. And in that sense, it’s a good thing, even though it’s going to take months, if not years, for it to unfold,” O’Dell told The Center Square.
“The worst case scenario is it’s a big, splashy headline that does nothing… and the best case scenario is that there’s real change that means that you actually pay less for the drugs that you need,” O’Dell told The Center Square. “That has not happened.”
TrumpRx may not help most Americans in the near-term, but O’Dell doesn’t think it was a wasted effort.
“The administration is hell bent on letting people know what they’re going to pay for health care before they go in and get it. And they’re turning that focus on to drugs. And that’s a good thing,” O’Dell said.
“They’re… casting eyes and a conceptual need for transparency onto one of the most opaque and unaffordable corners of health care… It’s a good thing, even though it’s going to take months, if not years, for it to unfold.”
And unlike many government reforms that have unintended consequences and can make the problem they’re trying to solve even worse, O’Dell doesn’t foresee that with these changes.
“There’s nothing in this that would ever make someone pay more or be worse off than before.”
Other necessary reforms
But O’Dell and others say American health care still desperately needs reforms in another area of the pharmaceutical industry: pharmacy benefit managers.
The Commonwealth Fund describes PBMs as “companies that work with health insurers, large employers, and other payers to manage their prescription drug benefits.” AI search assist says they “help to reduce prescription drug costs through price negotiations and utilization management.” But many in the health care industry say they actually inflate drug prices and simply “add another layer of secrecy” to the drug pricing process.
“We need to make the PBMs also put their rates out… Hospitals did it, payers did it, but the PBMs got away with not doing it. Why is that? And I would love to see the administration tackle that and say now you have to publish historical net price,” O’Dell said.
Miriam Paramore, founder of RxUtility, a website that helps insured Americans find and access prescription savings, also mentioned PBMs in an interview with The Center Square. Paramore thinks the administration’s announcement does address a driver of health care costs with MFN pricing. But a good next step would be PBM reform.
“What is as significant of a driver with the overall price of medications is also what you see in PBM reform. MFN pricing and PBM reform are big drivers of the cost of drugs,” Paramore said.
And so does PHRMA. It called PBMs and other federal programs the “real drivers of higher prices in the U.S.”
“PBMs get big discounts on medicines while charging patients full price. Hospitals abuse the 340B program to mark up drug prices by 700% or more. Addressing these abusive practices would dramatically lower drug prices for U.S. patients,” PHRMA said in a statement.
What’s next
TrumpRx is expected to launch in January 2026. The administration has said more deals with other drug manufacturers are underway.
Both Pfizer and AstraZeneca have pledged to invest tens of billions ($120 billion all told) in their manufacturing presence in the U.S. AstraZeneca just broke ground on a new, $4.5 billion plant that will make active pharmaceutical ingredients, most of which the U.S. currently gets from other countries like China and India.
These investments will shield those companies from tariffs for the next three years, as Trump has said companies that pledge significant American investment will be.
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.